Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review
S Martinelli, D Pascucci, P Laurenti - Frontiers in Public Health, 2023 - frontiersin.org
Background and objective The fourth dose the COVID-19 vaccine was first proposed to
immunocompromised patients. The aim of the article is to systematically review the literature …
immunocompromised patients. The aim of the article is to systematically review the literature …
Immunogenicity, clinical efficacy and safety of additional second COVID‐19 booster vaccines against Omicron and its subvariants: A systematic review
S Chenchula, MB Chandra… - Reviews in Medical …, 2024 - Wiley Online Library
The Omicron variant of severe acute respiratory syndrome coronavirus 2 is a new variant of
concern (VOC) and an emerging subvariant that exhibits heightened infectivity …
concern (VOC) and an emerging subvariant that exhibits heightened infectivity …
Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study
SW Jung, JJ Jeon, YH Kim, SJ Choe, S Lee - Nature Communications, 2024 - nature.com
The long-term association between mRNA-based coronavirus disease 2019 (COVID-19)
vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) …
vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) …
Susceptibility to COVID-19 and immunologic response to vaccination in patients with immune-mediated inflammatory diseases
Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of
diseases that share a common etiology of immune dysregulation, such as rheumatoid …
diseases that share a common etiology of immune dysregulation, such as rheumatoid …
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in adult patients with immune-mediated inflammatory diseases
MW Cheung, RM Dayam, JR Shapiro… - The Journal of …, 2023 - journals.aai.org
Previous studies have reported impaired humoral responses after SARS-CoV-2 mRNA
vaccination in patients with immune-mediated inflammatory diseases (IMIDs), particularly …
vaccination in patients with immune-mediated inflammatory diseases (IMIDs), particularly …
Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an …
JS Hanberg, X Fu, X Wang, NJ Patel… - The Lancet …, 2024 - thelancet.com
Background Patients with systemic autoimmune rheumatic diseases using disease-
modifying antirheumatic drugs (DMARDs) might have blunted responses to COVID-19 …
modifying antirheumatic drugs (DMARDs) might have blunted responses to COVID-19 …
Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19
N Ekström, TM Leino, A Juutinen, T Lehtonen, A Haveri… - Vaccines, 2024 - mdpi.com
Data on immune responses following COVID-19 booster vaccinations and subsequent
infections in the immunocompromised are limited. We studied antibody responses after the …
infections in the immunocompromised are limited. We studied antibody responses after the …
Vaccination in the Era of Immunosuppression
F Alnaimat, JJG Sweis, J Jansz, Z Modi, S Prasad… - Vaccines, 2023 - mdpi.com
Patients with autoimmune inflammatory rheumatic diseases (AIIRDs) are at increased risk
for severe infections. Vaccine responses and safety profiles may differ between AIIRD …
for severe infections. Vaccine responses and safety profiles may differ between AIIRD …
[HTML][HTML] The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review
SA SeyedAlinaghi, M Dashti, A Afzalian, H Siami… - Preventive Medicine …, 2024 - Elsevier
Introduction This study examines the efficacy and safety of three COVID-19 booster vaccines
including mRNA-based vaccines (BNT162b2 (BioNTech/Pfizer) and/or mRNA-1273 …
including mRNA-based vaccines (BNT162b2 (BioNTech/Pfizer) and/or mRNA-1273 …
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
H Kared, I Jyssum, A Alirezaylavasani… - Frontiers in …, 2024 - frontiersin.org
Background SARS-CoV-2 vaccination in rheumatoid arthritis (RA) patients treated with B cell-
depleting drugs induced limited seroconversion but robust cellular response. We aimed to …
depleting drugs induced limited seroconversion but robust cellular response. We aimed to …